Nov 12
Smallcap Short holds up to 6 small caps above $200M short, at $1 or more a share. Selection follows the model's composite negative factor. Returns are those of a short position in the basket, so the figure rises when the basket falls.
Equal capital goes into every position. The book is rebuilt each morning from the names the model expects to fall, and the orders are placed as market orders, so shorts and covers fill at the opening price. Positions are held for 6 to 8 days: they are not rotated out before day 6 and are covered by day 8. Every position carries a 40% stop on both sides. A short is covered if the price runs 40% above its entry, and equally if it falls 40% below it, filling at the first open after the level is touched. Reported returns are those of a short position in the basket: the position gains when the basket falls and loses when it rises. They are measured from those opening prices and include every stop exit. A short position's loss is not capped, and borrowing costs and stock-loan fees are not included.
H.C. Wainwright maintained a Buy rating and $65 price target post-Q3, well above the ~$20 trading level. The reiteration offers a modest counterweight to the selloff but is unlikely to reverse sentiment on its own.
Investing.comCitigroup analyst Yigal Nochomovitz maintained a Buy rating and lifted the price target to $3.4 from $3.1, implying substantial upside from the ~$1.8 trading level. Analyst PT increases typically draw incremental buying interest and validate the bull case near-term.
ScanXShares crossed above the 50-day moving average of $1.80, trading as high as $1.9178 on elevated volume of ~2.56M shares. A technical breakout above a key moving average can attract momentum traders and reinforce short-term upward pressure.
MarketBeatLegend reported Q3 2026 revenue of $359.5M (slightly above consensus) but a GAAP loss per share of $0.13 versus an expected near-breakeven, reversing Q2's first-ever profit. Shares fell roughly 10-16% as investors refocused on profitability durability; the miss is the dominant near-term price driver.
Investing.comOn the Q3 call, CFO Carlos Santos said Wall Street's 2027 Carvykti sales consensus sits at the "higher end" of internal scenarios, citing ex-U.S. launch delays and slower earlier-line U.S. share growth amid bispecific competition. The cautious forward tone compounds the earnings miss and pressures near-term estimates.
FiercePharmaQ3 release highlighted five-year CARTITUDE-2 Cohort A data (50% alive and progression-free off further treatment) and updated NCCN guidelines favoring CAR-T at first relapse, plus FDA IND clearance for LB2501 in vivo CAR-T. These support the long-term thesis but are secondary to near-term earnings concerns.
GlobeNewswire (Company Press Release)Zacks Research upgraded AerSale from strong sell to hold, and shares crossed above their 50-day moving average ($5.10) to trade around $5.18. The upgrade signals stabilizing sentiment after the post-earnings selloff, though the broader consensus remains cautious with a "Reduce" rating and $5.75 average price target.
MarketBeatOSG reported Q3 2026 revenue of $85.3M (+28% YoY), topping consensus, with adjusted net loss to shareholders narrowing to $(1.3)M or $(0.03)/share from $(10.0)M or $(0.21)/share a year ago. Insurance Distribution revenue grew 35% (23% organic) and Everspan swung to net income of $1.3M. The beat and margin improvement likely support positive short-term sentiment.
SEC Filing (Company Press Release, 8-K Ex. 99.1)On the Q3 2026 earnings call, management said it is "firmly on track" to exceed its 25%+ full-year organic growth guidance and now expects to exceed its $45M Insurance Distribution adjusted EBITDA guidance, while reiterating confidence in the $80M consolidated adjusted EBITDA target for 2028. Upward guidance commentary is typically a positive near-term catalyst.
StockAnalysis (Q3 2026 Earnings Call Transcript)At AHA Scientific Sessions, Lexicon presented data showing sotagliflozin reduced arterial-like clot formation by 11.9% and venous-like by 15.6% in healthy adults, with empagliflozin not reaching significance. The data support the dual SGLT1/2 mechanism ahead of SONATA-HCM topline results, reinforcing the pipeline narrative.
ScanXLexicon reported Q3 2026 EPS of -$0.03 versus the -$0.06 consensus and revenue of $11.25M versus $2.83M expected, driven largely by a $10M Novo milestone. The beat, combined with $183.2M in cash and reiterated Q1 2027 SONATA-HCM topline timing, is a positive near-term sentiment driver.
Lexicon Pharmaceuticals Press ReleaseHC Wainwright analyst J. Pantginis raised the FY2026 EPS estimate to -$0.14 from -$0.15, above the -$0.16 consensus. A favorable estimate revision signals improving fundamentals perception and can support near-term sentiment.
MarketBeatHello Group will report Q3 2026 unaudited results before U.S. markets open on Dec 7, 2026, with a conference call at 6:00 a.m. ET. This is the key near-term catalyst; investor focus will be on whether results land within the guided RMB2.4-2.5 billion range and on overseas growth trajectory.
PR Newswire (via Yahoo Finance)AerSale reported Q3 2026 revenue of $91.56M (up 28.6% YoY, roughly in line with consensus), but adjusted EPS of -$0.02 versus $0.11 expected and adjusted EBITDA of $8.56M versus $14.04M consensus (a ~39% miss). The weak profitability drove a 10.5% share drop to $4.33 immediately after the release, pressuring near-term sentiment.
AerSale Press Release (GlobeNewswire)Q3 results included a $13.4M non-cash goodwill impairment charge representing the full goodwill balance in the Asset Management segment, triggered by the sustained decline in stock price and market capitalization. Management stated it does not affect liquidity or debt covenant compliance, but it drove the reported net loss of $15.0M and headline EPS of -$0.31.
The Motley Fool (Earnings Call Transcript)Management guided to a significantly stronger Q4, citing commitments for a $35M Boeing 737 sale to the U.S. Marshals Service and additional engine sales in final restoration stages, with the Flight Equipment pipeline expected to close before year-end. Successful closing would improve liquidity (currently $23.1M) and could support a near-term re-rating if execution is confirmed.
Seeking AlphaOn Oct 31, 2026, StoneX analyst Fawne Jiang kept a Buy rating but lowered the price target from $10 to $8, reflecting a more cautious valuation view. The cut signals tempered expectations ahead of Q3 earnings, though the Buy rating and $8 target remain well above the ~$4.59 recent price.
Fiscal.aiCitizens lowered its DBVT price target to $47 from $55 while maintaining a Market Outperform rating, citing BLA timing/delay concerns. The reduced target still implies substantial upside from ~$10.65, but the cut signals tempered near-term expectations around the regulatory timeline.
Investing.comDBV submitted the BLA for the VIASKIN Peanut Patch (ages 4-7) on Sept 29, 2026 and requested Priority Review. The FDA is expected to determine in Q4 2026 whether the filing is sufficiently complete to begin substantive review and whether Priority Review is granted. A positive acceptance/Priority Review decision would be a near-term binary catalyst likely to lift shares, while a refusal-to-file or standard-review designation would pressure the stock.
DBV Technologies Press ReleaseIn Q3 2026 results, management concluded existing cash ($165.7M as of Sept 30) is insufficient to fund operations for at least twelve months, raising substantial doubt about going concern despite runway into Q3 2027. The company is evaluating ATM sales, equity transactions, and warrant exercises, creating near-term dilution overhang that weighed on shares (down ~8% post-report).
DBV Technologies Press ReleaseDBV continues remediation work with contract manufacturer Fareva following the April 2026 FDA Warning Letter; the target PAI date in the BLA falls after Fareva expects to complete remediation. Any negative FDA feedback on manufacturing readiness or PAI scheduling could threaten approval timing and pressure shares.
DBV Technologies Press ReleaseDBV is discussing a potential rolling submission for the 1-through-3 year toddler BLA, with submission expected in 2027 and an update pending finalization of FDA discussions. Progress here supports the broader franchise narrative but is unlikely to be an immediate price mover within two weeks.
DBV Technologies Press ReleaseEverspan entered into an agreement to sell its redundant admitted shell carrier, Providence Washington Insurance Company, expected to close by early next year. Management expects a consolidated net gain of close to $4M and an increase to Everspan's tangible book value of approximately $11M, simplifying structure and strengthening capital — a modest positive.
SEC Filing (Form 10-Q)Management guided Q3 2026 total net revenues to RMB2.4-2.5 billion, a 9.4% to 5.7% year-over-year decrease, a steeper decline than Q2's 5.1% drop. The decelerating domestic trend sets a low bar into the Dec 7 report and could pressure shares if overseas growth does not offset domestic weakness.
Hello Group Press Release (Q2 2026 Results)As of Sept 3, 2026, the company had repurchased 68.0 million ADSs for $424.1 million at an average of $6.22 per ADS, with $62.0 million remaining under the program. Continued buyback execution provides modest downside support and a potential positive signal around the earnings date.
Hello Group Press Release (Q2 2026 Results)The board appointed Mr. Jianhua Wen as chief operating officer effective Sept 3, 2026, ceasing his role as chief technology officer. The operational leadership change is a minor governance event; market impact is likely limited but worth monitoring for execution on the overseas growth strategy.
Hello Group Press Release (Q2 2026 Results)